ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $314,162 | -0.3% | 3,355 | -5.0% | 0.00% | – |
| Q2 2023 | $315,231 | -17.9% | 3,532 | -1.4% | 0.00% | – |
| Q1 2023 | $383,955 | -9.2% | 3,581 | +3.5% | 0.00% | – |
| Q4 2022 | $422,692 | -8.7% | 3,461 | -22.7% | 0.00% | – |
| Q3 2022 | $463,000 | +5.7% | 4,480 | -5.0% | 0.00% | – |
| Q2 2022 | $438,000 | -24.4% | 4,716 | -4.4% | 0.00% | – |
| Q1 2022 | $579,000 | -85.6% | 4,934 | -83.5% | 0.00% | -100.0% |
| Q4 2021 | $4,028,000 | -11.5% | 29,942 | +4.9% | 0.00% | -25.0% |
| Q3 2021 | $4,550,000 | +33.1% | 28,544 | +9.8% | 0.00% | +33.3% |
| Q2 2021 | $3,419,000 | +10.1% | 25,987 | +7.8% | 0.00% | 0.0% |
| Q1 2021 | $3,106,000 | -12.0% | 24,103 | +13.9% | 0.00% | -25.0% |
| Q4 2020 | $3,529,000 | +10.9% | 21,161 | +2.6% | 0.00% | 0.0% |
| Q3 2020 | $3,183,000 | +1272.0% | 20,629 | +1212.3% | 0.00% | – |
| Q2 2020 | $232,000 | +6.4% | 1,572 | +0.3% | 0.00% | – |
| Q4 2019 | $218,000 | -36.1% | 1,567 | -45.9% | 0.00% | -100.0% |
| Q1 2019 | $341,000 | – | 2,895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |